Conclusions: In this case, the clinical presentation was markedly different from the expected suppressive effects of GnRH agonist therapy, with profoundly elevated estrogen levels and clinical signs of imminent OHSS. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.